stockrowGuardant Health, Inc.
GH Healthcare Diagnostics & Research
Guardant Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $982.0 million, up 32.9% from fiscal 2024.
- Revenue
- +36.1%
- EPS
- −25.7%
- Free cash flow
- +18.7%
- Total debt
- +34.8%
Quarter to September 2026, against a year earlier
Follow GH
Alert me
Guardant Health, Inc. (GH) Revenue
Guardant Health, Inc.'s revenue for fiscal 2025 was $982.0M, up 32.9% from $739.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.3B. Over the past ten years it has ranged from $25.2M (fiscal 2016) to $982.0M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 9 consecutive fiscal years. Guardant Health, Inc. ranks 18th of 47 Diagnostics & Research companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $982.0M | 32.88% |
| FY2024 | $739.0M | 31.04% |
| FY2023 | $563.9M | 25.45% |
| FY2022 | $449.5M | 20.31% |
| FY2021 | $373.7M | 30.32% |
| FY2020 | $286.7M | 33.75% |
| FY2019 | $214.4M | 136.52% |
| FY2018 | $90.6M | 81.85% |
| FY2017 | $49.8M | 97.40% |
| FY2016 | $25.2M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $361.0M | 7.76% |
| Jun 2026 | $335.0M | 11.04% |
| Mar 2026 | $301.7M | 7.25% |
| Dec 2025 | $281.3M | 6.06% |
| 32 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| LH Labcorp Holdings Inc. compare | $14.6B |
| DGX Quest Diagnostics Incorporated compare | $11.8B |
| ICLR ICON PLC compare | $8.2B |
| ILMN Illumina, Inc. compare | $4.5B |
| MTD Mettler-Toledo International, Inc. compare | $4.1B |
| CRL Charles River Laboratories International, Inc. compare | $4.0B |
| RVTY Revvity Inc. compare | $2.9B |
| MEDP Medpace Holdings, Inc. compare | $2.8B |
| GH Guardant Health, Inc. | $1.3B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on GH
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement